Advertisement

Topics

Similar Efficacy for Key Anti-VEGF Agents in Macular Edema

05:28 EDT 20 Jun 2017 | Medscape

The SCORE2 trial shows that bevacizumab and aflibercept may produce similar short-term outcomes. Here is a closer look at its results.
Medscape Optometry

Original Article: Similar Efficacy for Key Anti-VEGF Agents in Macular Edema

NEXT ARTICLE

More From BioPortfolio on "Similar Efficacy for Key Anti-VEGF Agents in Macular Edema"

Advertisement
Quick Search
Advertisement
Advertisement